Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.33 |
| ▸ | KYNU | Q16719 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769684 | 1.00 | PTGS1 (0.39) | PTGS1SLC7A11GSRCA12CA14 | |
| SCHEMBL13584711 | 0.89 | GSR (0.44) | PTGS1SLC7A11GSRCA12CA14 | |
| SCHEMBL1769560 | 0.89 | GSR (0.44) | PTGS1SLC7A11GSRCA12CA14 | |
| SCHEMBL1769608 | 0.85 | CA12 (0.38) | PTGS1SLC7A11GSRCA12CA14 | |
| SCHEMBL1769605 | 0.85 | CA12 (0.38) | PTGS1SLC7A11GSRCA12CA14 | |
| SCHEMBL1769565 | 0.85 | GSR (0.47) | PTGS1SLC7A11GSRGABRR1PMP22 | |
| SCHEMBL1769561 | 0.85 | GSR (0.47) | PTGS1SLC7A11GSRGABRR1PMP22 | |
| SCHEMBL1769392 | 0.80 | CASR (0.39) | CA12CA14CA7CA9PMP22 | |
| SCHEMBL1769599 | 0.80 | CA12 (0.44) | CA12CA14CA7CA9PMP22 | |
| SCHEMBL13585191 | 0.80 | ALDH1A1 (0.42) | CA12CA14CA7CA9PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | PTGS1 1952/4885SLC7A11 424/4885GSR 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.